Abbott And Sanofi To Connect Diabetes Technologies
Executive Summary
Abbott and Sanofi are partnering up to develop a new connected diabetes device. The non exclusive collaboration will combine Abbott’s FreeStyle Libre continuous glucose monitoring system with Sanofi’s connected insulin pens and software currently under development.
You may also be interested in...
Diabetes, Mitral Repair And Diagnostics Drive Big Quarter For Abbott
Abbott Laboratories’ medical device businesses grew 10.6% year over year in the third quarter of 2019 while its diagnostics business grew 6.6%, helping the company grow 7.6% overall, the company reported on 16 October.
Abbott Signs Partnership With Omada To Expand FreeStyle Libre Users
Abbott signed a deal with Omada Health to integrate Abbott's FreeStyle Libre with Omada's health coaching platform.
DreaMed Receives Another FDA Clearance For AI-Powered Diabetes Software
Israeli firm DreaMed has scored a new US Food and Drug Administration clearance for its AI-based diabetes decision support system Advisor Pro. The clearance enables physicians to use the software for patients with type 1 diabetes using continuous glucose monitoring (CGMs) and blood glucose meters (BGMs).